Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Next Previous
Search
Trial Profile

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ponatinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms OPTIC
  • Sponsors ARIAD Pharmaceuticals; Takeda Development Center Americas; Takeda Pharma

    • Most Recent Events

    • 08 Jan 2025 Planned End Date changed from 31 Dec 2024 to 31 Mar 2025.
    • 25 Nov 2024 According to a Takeda media release, five-year follow-up of the Phase 2 OPTIC study providing updated long-term efficacy and safety data of ICLUSIG (ponatinib) in patients with chronic-phase chronic myeloid leukemia will be presented at the 66th American Society of Hematology Annual Meeting being held December 7-10, 2024, in San Diego, California.
    • 25 Nov 2024 According to a Takeda media release, data from this study will be presented at the 66th American Society of Hematology (ASH) Annual Meeting being held December 7-10, 2024, in San Diego, California.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top